DC-NANOCHON
6.5.2024 17:01:26 CEST | Business Wire | Press release
Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round.
The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others.
Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team.
“We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care.”
Nanochon will initiate a phase I trial in the US this year for its patented knee implant Chondrograft™. The device requires only minimally invasive surgery to regrow damaged cartilage and bone to stave off the need for full knee replacements which are costly and have a long recovery time.
Holmes follows, “We’ve had fantastic success in our animal studies and we’re very optimistic about future implications in human knees and other joints.”
Nanochon is a biotech and medical device company focused on developing innovative orthopedic solutions. Chondrograft™ is a minimally-invasive implant that allows for immediate weight-bearing and motion – meaning less time spent recovering. Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care. Our mission is to develop a new approach to treat cartilage replacement and repair so that the hundreds of thousands of young, active patients with joint damage can return to their lifestyles without having to undergo costly and invasive short-term fixes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503575444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Inc. to Host Third Quarter 2026 Financial Results Conference Call on November 5, 202613.10.2026 14:30:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced that it has scheduled a conference call to discuss its financial results for the third quarter ended September 30, 2026. The call will be hosted on Thursday, November 5, 2026, at 8:30 a.m. Eastern Time by Razat Gaurav, Chief Executive Officer, and Herb Yeh, Chief Financial Officer and Chief Strategy Officer, followed by a question and answer period. The Company will report its financial results for the third quarter after the close of markets on Wednesday, November 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, November 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/703967106 About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniqu
ExaGrid Announces Record 3rd Quarter Bookings and Revenue13.10.2026 14:00:00 CEST | Press release
ExaGrid Achieves 23rd Consecutive Quarter of Free Cash Flow, EBITDA, and P&L Positive Operations ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the fastest backups, fastest restores, largest backup storage scale-out system with deduplication, and the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it had its best ever third quarter for bookings and revenue in the quarter ending September 30, 2026, with double-digit revenue growth over Q3 of 2025 and double-digit revenue growth for the first nine months of 2026 over 2025. ExaGrid has exceeded its plan in all three quarters of 2026 and is ahead of plan on its way to a record bookings and revenue year. ExaGrid’s growth rate is accelerating. In addition, ExaGrid remained P&L, EBITDA, and free cash flow positive for the 23rd consecutive quarter. The company is 100% debt-free, demonstrating strong financial health as a company.
Seequent Launches AI-Powered Imago Image Analysis to Accelerate Geological Core Logging13.10.2026 14:00:00 CEST | Press release
New AI capability embedded directly into Imago workflows transforms drill core imagery into consistent, quantitative geological data in minutes, helping exploration teams make more confident drilling decisions Seequent, The Bentley Subsurface Company, has launched Imago image analysis, a new AI-powered capability built directly into its cloud-based solution Imago for extracting knowledge from geoscientific imagery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013282684/en/ Imago image analysis results showing core condition, fracture polylines, and AutoCrop boundaries on diamond-drilled core. Core condition delineates solid (blue), broken (orange), depth blocks (green), and gaps in recovered core. With the new Imago image analysis add-on, geologists can analyse drill core imagery in minutes, dramatically accelerating analysis that has traditionally taken days or weeks. It generates consistent, high-confidence quantitati
What Europeans Really Want From Their Next Smartphone13.10.2026 13:01:00 CEST | Press release
New research from Samsung shows that Europeans are choosing smartphones with two things in mind: their life today and what they want to do next If you’ve ever bought running shoes for the runner you hoped to become or luggage for a yet to be planned trip, you’re not alone. New research from Samsung reveals that Europeans1 take a similar aspirational approach when choosing a smartphone. More than two thirds (66%2) of Europeans surveyed1 chose their current smartphone with at least one interest they wanted to pursue in mind, with interests ranging from entertainment and side hustles to gaming, travel and content creation. In fact, almost half (46%3) consider their ambitions when making technology choices, including 24% who say their choices are primarily shaped by the life they aspire to lead. Additionally, almost a third (28%) reported that they chose their current smartphone to better reflect their personal style. Having a variety of options to choose from is important when considering
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules13.10.2026 13:00:00 CEST | Press release
Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, today announced it has entered into a research collaboration and license agreement with Pfizer Inc. to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule therapeutics leveraging Enodia’s proprietary platform. Enodia’s proprietary platform enables selective Sec61 Translocon modulation, a novel approach to inhibit disease-driving proteins at the point of synthesis before pathological effects occur, while preserving essential physiological functions. Enodia has built a broad and well-characterized chemical space spanning multiple Sec61 inhibitor families, supported by extensive biological datasets, including proteomics, cryo-EM and tailored cell-line libraries that enable rational small-molecule design powered by machine learning. “Enodia has built a broad platform t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom